Logo

Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Share this

Vir Reports First Patient Dosing in P-II MARCH Trial for VIR-2218 + VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Shots:

  • The 1st patient has been dosed in the P-II MARCH trial evaluating safety- tolerability & efficacy of VIR-2218 + VIR-3434 (SC) in ~90 patients aged 18-65yrs. with chronic HBV infection for 4-20wks. & follow-up period of ~116 wks.- depend on dosing cohort
  • The 1EPs of a trial is the proportion of patients with AEs & SAEs- grading of post-treatment clinical laboratory parameters & proportion of patients achieving a functional cure
  • VIR-2218 is an investigational HBV-targeting siRNA & VIR-3434 is an HBV-neutralizing mAb designed to block entry of all 10 genotypes of HBV into hepatocytes- as well as reduce the level of virions and subviral particles in the blood

 Ref: Vir | Image: Fierce Biotech

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions